American Red Cross, Scientific Affairs, Gaithersburg, Maryland, USA.
Quality Analytics, Deerfield, Illinois, USA.
J Infect Dis. 2022 Jan 5;225(1):5-9. doi: 10.1093/infdis/jiab514.
From December 2020 to June 2021, 1654487 blood donors were tested for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S1 protein, and 1028547 (62.17%) were reactive. A rapid increase in prevalence was due to vaccination. Among a subset of 1567446 donors, 729771 (46.56%) reported SARS-CoV-2 vaccination, of whom 633769 (86.84%) were S1-antibody reactive only in response to vaccination and 68269 (9.35%) were reactive to both S1 and nucleocapsid in response to prior infection; the remainder were not reactive to either antibody. Among the 837675 (53.44%) donors who did not report vaccination, 210022 (25.07%) had reactivity to both antibodies and 29446 (3.52%) to S1 only.
从 2020 年 12 月到 2021 年 6 月,共有 1654487 名献血者接受了严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)S1 蛋白抗体检测,其中 1028547 名(62.17%)呈反应性。患病率的快速上升归因于疫苗接种。在 1567446 名献血者的一个亚组中,有 729771 名(46.56%)报告接种了 SARS-CoV-2 疫苗,其中 633769 名(86.84%)仅因接种而对 S1 抗体呈反应性,68269 名(9.35%)因先前感染而对 S1 和核衣壳均呈反应性;其余两者均无反应。在未报告接种疫苗的 837675 名(53.44%)献血者中,有 210022 名(25.07%)对两种抗体均呈反应性,有 29446 名(3.52%)仅对 S1 呈反应性。